[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

731.O3.6 731. Clinical Allogeneic and Autologous Transplantation - Results: Novel Regimens and Prognostic Scoring

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 2:45 PM-4:15 PM
Douglas Pavilion C (Manchester Grand Hyatt San Diego)
Moderators:
Ginna G. Laport, MD, Stanford University and Steven M. Devine, MD, The Ohio State University Comprehensive Cancer Center

Disclosures:
No relevant conflicts of interest to declare.
2:45 PM
Randomized Phase III Trial of 131iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Julie M Vose, MD1, Shelly L Carter, ScD2*, Linda J Burns, MD3, Ernesto Ayala, MD4, Oliver W. Press, MD, PhD5, Craig H. Moskowitz, MD6, Edward A. Stadtmauer, MD7, Shin Mineishi, MD8, Richard F. Ambinder9, Timothy S. Fenske, MD10, Mary M. Horowitz, MD, MS11 and Marcie Tomblyn, MD, MS12

1Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE
2The EMMES Corporation, Rockville, MD
3Medicine, University of Minnesota Medical Center, Minneapolis, MN
4Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Lymphoma and Adult BMT Services, Memorial Sloan-Kettering Cancer Center, New York, NY
7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
8Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI
9Johns Hopkins University, Baltimore, MD
10Medical College of Wisconsin, Milwaukee, WI
11Medicine, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI
12Dept. of Blood & Marrow Transplantation, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

3:00 PM
Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results

Issa F Khouri, MD1, Rima M Saliba, Ph.D.2*, Rosamar Valverde3*, Barry I Samuels, MD4*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Paolo Anderlini, MD1, Qaiser Bashir, MD1*, Marcos De Lima, MD5, Chitra Hosing, MD6, Partow Kebriaei, MD7, Yago Nieto, MD, PhD2, Uday R Popat, MD2, Muzaffar Qazilbash, MD1, Sattva Neelapu, MD8, Nathan H. Fowler, MD6, Felipe Samaniego, MD8, Luhua Wang, MD9, Richard Champlin, MD1 and Homer A Macapinlac, MD10*

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Stem Cell Transplantation and Cellular Therapy , The University of Texas MD Anderson Cancer Center, Houston , TX
4Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center , Houston, TX
6The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX
8Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
9Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
10Nuclear Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX

3:15 PM
A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Ajay K. Gopal, MD1, Ted Gooley2*, Joseph Rajendran, MD3*, John M. Pagel, MD, PhD4, Darrell R. Fisher, PhD5*, David G. Maloney, MD, PhD6, Frederick R. Appelbaum, MD6, Andrew Shields, MD3* and Oliver W. Press, MD, PhD7

1Medical Oncology, University of Washington, Seattle, WA
2Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA
3University of Washington, Seattle, WA
4Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
5Pacific Northwest National Laboratory , Richland, WA
6Fred Hutchinson Cancer Research Center, Seattle, WA
7Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA

3:30 PM
Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD1, Stephen J. Forman, MD1, Joycelynne Palmer, PhD2*, Ni-Chun Tsai, MS2*, Leslie Popplewell, MD1*, Maria L Delioukina, MD1*, Torres Alejandra, MS3*, Bernadette Pulone, RN, OCN1*, Eileen P. Smith, MD1, Auayporn P. Nademanee, MD1, Chatchada Karanes, MD4, Paul O'Donnell, MD, PhD5*, David G. Maloney, MD, PhD6, Len Farol, MD7*, Schickwann Tsai, MD, PhD8, Laurie E. Grove, PA-C9* and Ajay K. Gopal, MD5

1Hematology and HCT, City of Hope National Medical Center, Duarte, CA
2Division of Biostatistics, City of Hope National Medical Center, Duarte, CA
3Hematology and HCT, City of Hope National Medical Center, Pasadena, CA
4Hematology and HCT, City of Hope, Duarte, CA
5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Fred Hutchinson Cancer Research Center, Seattle, WA
7City of Hope Medical Center/So California Permanente Medical Group, Duarte, CA
8Internal Medicine, University of Utah, salt lake city, UT
9Seattle Genetics, Inc., Bothell, WA

3:45 PM
Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) OutcomesClinically Relevant Abstract

Fabiana Ostronoff, MD1, Barry Storer, PhD1,2*, Rainer Storb, MD2,3, Smita Bhatia, MD, MPH4, Richard T. Maziarz, MD5, Michael A. Pulsipher, MD6, Michael T. Maris, MD7, H. Joachim Deeg, MD1,2, Paul J. Martin, MD1,2, Frederick R. Appelbaum, M.D.1,2, David G. Maloney, MD, PhD1,2, Brenda M. Sandmaier, MD1,2 and Mohamed L. Sorror, MD, MSc1,2

1Fred Hutchinson Cancer Research Center, Seattle, WA
2University of Washington, Seattle, WA
3Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
4City of Hope, Duarte, CA
5Oregon Health and Science University, Portland, OR
6University of Utah, Salt Lake City, UT
7Rocky Mountain Cancer Center, Denver, CO

4:00 PM
Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)

H. Joachim Deeg, MD1, Bart Lee Scott, MD2, Frederick R. Appelbaum, MD1 and Ted Gooley3*

1Fred Hutchinson Cancer Research Center, Seattle, WA
2Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA
3Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA

*signifies non-member of ASH